These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28968921)

  • 1. Reply to Kadri Altundag.
    Yoshida A; Hayashi N
    J Surg Oncol; 2018 Feb; 117(2):329. PubMed ID: 28968921
    [No Abstract]   [Full Text] [Related]  

  • 2. In reply to Kadri Altundag.
    Cazzaniga ME
    Breast Cancer Res Treat; 2017 Jan; 161(2):387. PubMed ID: 27873134
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?
    Grassadonia A; Vici P; Gamucci T; Moscetti L; Pizzuti L; Mentuccia L; Iezzi L; Scognamiglio MT; Zilli M; Giampietro J; Graziano V; Natoli C; Tinari N
    Breast; 2017 Oct; 35():218-219. PubMed ID: 28526175
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Dr Altundag from the authors of 'Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival'.
    Kindts I; Weltens C
    Breast; 2017 Dec; 36():103. PubMed ID: 28189299
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Dr Altundag from the authors of 'Management of breast cancer brain metastases; a practical review'.
    Phillips C; Jeffree R; Khasraw M
    Breast; 2017 Aug; 34():133. PubMed ID: 27955975
    [No Abstract]   [Full Text] [Related]  

  • 6. A Positive Conversion of Hormone Receptor Status Might Improve Survival after Liver Resection for Breast Metastases: Reply to Dr. Altundag.
    Ercolani G
    Dig Surg; 2019; 36(1):90. PubMed ID: 29597207
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to K. Altundag.
    Underwood EA; Tierney MC
    Breast Cancer Res Treat; 2018 May; 169(1):205. PubMed ID: 29411236
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Comment on 'Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'.
    Heil J
    Br J Cancer; 2016 May; 114(10):e4. PubMed ID: 27092782
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.
    Fujii T; Ueno NT
    Br J Cancer; 2017 Apr; 116(8):e11. PubMed ID: 28291772
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply:
    Chae SY; Kim SB; Ahn SH; Moon DH
    J Nucl Med; 2017 Apr; 58(4):683-684. PubMed ID: 27932559
    [No Abstract]   [Full Text] [Related]  

  • 11. In Reply to Mailhot et al.
    Stecklein SR; Shaitelman SF
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1281. PubMed ID: 30900563
    [No Abstract]   [Full Text] [Related]  

  • 12. In reply to: Anti-HER2 neoadjuvant treatment may have an impact on discordance between preoperative core needle biopsy and surgical specimen in early breast cancer.
    Meattini I; Francolini G; Livi L; Nori J
    Eur J Surg Oncol; 2017 Jun; 43(6):1143-1144. PubMed ID: 28262275
    [No Abstract]   [Full Text] [Related]  

  • 13. Some pathological and clinical factors are important to describe association between Ki67 expression and recurrences in breast cancer patients receiving neoadjuvant chemotherapy-reply.
    Horimoto Y
    Hum Pathol; 2017 Oct; 68():205. PubMed ID: 28606455
    [No Abstract]   [Full Text] [Related]  

  • 14. HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?-reply.
    Xian Z; Zynger DL
    Hum Pathol; 2017 Jul; 65():247-248. PubMed ID: 28438618
    [No Abstract]   [Full Text] [Related]  

  • 15. In Reply.
    Elliott RM; Shenk RR; Thompson CL; Gilmore HL
    Arch Pathol Lab Med; 2015 Jul; 139(7):845-6. PubMed ID: 26125421
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to A. Pfob et al.
    Meti N; Sadeghi-Naini A; Tran WT
    JCO Clin Cancer Inform; 2021 Jun; 5():656-657. PubMed ID: 34110932
    [No Abstract]   [Full Text] [Related]  

  • 17. In Reply.
    Dang CT; Singh JC; Steingart RM; Yu AF
    Oncologist; 2018 Dec; 23(12):e165-e166. PubMed ID: 30120162
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice.
    Cain H; Macpherson IR; Beresford M; Pinder SE; Pong J; Dixon JM
    Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):642-652. PubMed ID: 28669449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy for breast cancer.
    Liu SV; Melstrom L; Yao K; Russell CA; Sener SF
    J Surg Oncol; 2010 Mar; 101(4):283-91. PubMed ID: 20187061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply: Semiquantification Limitations: FMTVDM
    Humbert O; Brunotte F; Cochet A
    J Nucl Med; 2018 Oct; 59(10):1644. PubMed ID: 30166356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.